VENTRUS BIOSCIENCES INC

Inactive Instrument

Analyst Reco. Ventrus Biosciences Inc Nasdaq

Equities

US9228221019

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Mar. 28	Assembly Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Jan. 19	Assembly Biosciences Insider Bought Shares Worth $511,264, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Adjusts Price Target on Assembly Biosciences to $1.50 From $2.50, Keeps Neutral Rating	23-03-24	MT
Mizuho Cuts Price Target on Assembly Biosciences to $3 From $14, Keeps Buy Rating	22-11-15	MT
Truist Securities Downgrades Assembly Biosciences to Hold From Buy, Adjusts Price Target to $2 From $11	22-10-24	MT
HC Wainwright Adjusts Assembly Biosciences Price Target to $2.50 From $3,50, Maintains Buy Rating	22-07-21	MT
Truist Securities Adjusts Assembly Biosciences Price Target to $12 From $15, Maintains Buy Rating	22-04-01	MT
ASSEMBLY BIOSCIENCES : HC Wainwright Starts Assembly Biosciences at Neutral with $3.50 Price Target	21-09-13	MT
ASSEMBLY BIOSCIENCES : William Blair Downgrades Assembly Biosciences to Market Perform From Outperform	21-09-02	MT
ASSEMBLY BIOSCIENCES : Mizuho Securities Adjusts Price Target on Assembly Biosciences to $14 From $13 on Lower Expenses, Reiterates Buy Rating	21-08-12	MT
ASSEMBLY BIOSCIENCES : SVB Leerink Adjusts Price Target for Assembly Biosciences to $7 From $8, Maintains Market Perform Rating	21-05-10	MT
ASSEMBLY BIOSCIENCES : SVB Leerink Downgrades Assembly Biosciences to Market Perform From Outperform, Adjusts PT to $8 From $9	21-03-23	MT
ASSEMBLY BIOSCIENCES : Jefferies Adjusts Price Target for Assembly Biosciences to $7 From $10, Maintains Hold Rating	20-12-21	MT
ASSEMBLY BIOSCIENCES : Mizuho Adjusts Assembly Biosciences' PT to $13 From $30 After H0731 'Failure in Finite Therapy;' Buy Rating Kept on Undervalued Chronic Suppressive Therapy	20-12-04	MT
ASSEMBLY BIOSCIENCES : Jefferies Downgrades Assembly Biosciences to Hold From Buy; Price Target is $10	20-11-06	MT
Assembly Biosciences, Inc. Announces Results from Research Study Evaluating the Turnover Rate of Covalently Closed Circular DNA, Which Plays Pivotal Role in the Establishment and Persistence of HBV Infection	20-04-06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Discover our Free Content to Help You Better Understand the Stock Market.

100% Free Registration

fermer